|
Oct 9
|
Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society
|
|
Sep 24
|
Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development
|
|
Jul 25
|
Wall Street Analysts See a 25.73% Upside in Entrada Therapeutics (TRDA): Can the Stock Really Move This High?
|
|
Jun 27
|
With 40% ownership, Entrada Therapeutics, Inc. (NASDAQ:TRDA) has piqued the interest of institutional investors
|
|
Jun 24
|
Entrada Therapeutics Announces $100 Million Registered Direct Offering
|
|
Jun 24
|
Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy
|
|
Feb 7
|
Entrada Therapeutics to Present at Upcoming Investor Conferences
|
|
Dec 29
|
Amicus (FOLD) Banks on Galafold, Overdependence a Concern
|
|
Dec 28
|
Iovance (IOVA) Falls After Clinical Update on Lung Cancer Drug
|
|
Dec 28
|
Coherus (CHRS) Stock Rallies on FDA Nod for Udenyca Onbody
|
|
Dec 28
|
Entrada Therapeutics Inc CFO Kory Wentworth Sells 12,500 Shares
|
|
Dec 22
|
Sanofi (SNY) Discontinues Tusamitamab Ravtansine Cancer Program
|
|
Dec 21
|
argenx (ARGX) Tanks on Top-Line Data From Pemphigus Study
|
|
Dec 20
|
Roche's (RHHBY) sBLA for Xolair Gets FDA Priority Review Tag
|
|
Dec 20
|
Anavex (AVXL) Rises as CHMP Deems Blarcamesine Eligible for MAA
|
|
Dec 19
|
Invivyd (IVVD) Surges on Positive Data From COVID-19 Study
|
|
Dec 19
|
Mirum (MIRM) Down on Failure of Mid-Stage Study on Livmarli
|
|
Dec 15
|
Apellis (APLS) Falls on Europe Update for Pegcetacoplan in GA
|
|
Dec 14
|
Amgen's (AMGN) Tarlatamab BLA Gets FDA Priority Tag for SCLC
|
|
Dec 13
|
C4 Therapeutics (CCCC) Soars on Oncology Deal With Merck
|